Bleich, Lene http://orcid.org/0009-0007-9585-4744
Grohmann, Renate
Greil, Waldemar http://orcid.org/0000-0003-2342-735X
Dabbert, Dominik
Erfurth, Andreas http://orcid.org/0000-0003-3870-3521
Toto, Sermin http://orcid.org/0000-0002-8859-6907
Seifert, Johanna http://orcid.org/0000-0002-8678-7419
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
Article History
Received: 14 May 2024
Accepted: 31 July 2024
First Online: 13 August 2024
Declarations
:
: S. Toto is the project manager of the AMSP program and a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker’s honoraria from Janssen-Cilag, Lundbeck/Otsuka, Recordati Pharma GmbH, ROVI, and Servier. D. Dabbert has received speaker’s honoraria from Aristo. A. Erfurth has received honoraria for advisory board membership and/or speaker fees from Angelini, Boehringer Ingelheim, Germania, Janssen, Lundbeck, Mylan, Neuraxpharm, Recordati, Rovi and Sandoz. All other authors state they have no competing interests to declare that are relevant to the content of this article.
: The AMSP project and the evaluation of the collected data were authorized by AMSP representatives from Germany, Austria, and Switzerland and the ethics committees of the Ludwig-Maximilians-University of Munich and Hannover Medical School (Nr. 8100_BO_S_2018). This study adheres to the Declaration of Helsinki and its later adaptions. The AMSP program in no way interferes with the treatment of hospitalized patients due to its nature of being an observational post-marketing drug surveillance program. Moreover, data used in this study was obtained from the anonymized data bank of the AMSP program and therefore, individual patients cannot be retraced.